Low-dose aspirin for early COVID-19: does the early bird catch the worm?

Expert Opin Investig Drugs. 2021 Aug;30(8):785-788. doi: 10.1080/13543784.2021.1950687. Epub 2021 Jul 12.

Authors

John G Rizk¹, Carl J Lavie², Ajay Gupta³

Affiliations

¹ Arizona State University, Edson College, Phoenix, AZ, USA.
² John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA, USA.
³ Division of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, School of Medicine, Irvine, CA, USA.

PMID: 34190669
DOI: 10.1080/13543784.2021.1950687

No abstract available

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
Aspirin / administration & dosage*
COVID-19 / metabolism
COVID-19 Drug Treatment*
Dose-Response Relationship, Drug
Humans
Randomized Controlled Trials as Topic / methods
SARS-CoV-2 / drug effects*
SARS-CoV-2 / metabolism

Substances

Anti-Inflammatory Agents, Non-Steroidal
Aspirin